TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8571936

Group type: EXPERIMENTAL
Intervention: rh IFN alpha‐2b (150 x 10(4) IU: 3 MIU) administered three times a week
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: rh IFN alpha‐2b (300 x 10(4) IU: 3 MIU) administered three times a week
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: rh IFN alpha‐2b (3 MIU) administered once a week for 8 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Any administration schedule of rh IFN alpha‐2b
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Once a week administration schedule of rh IFN alpha‐2b
Number of subjects: 50
Study: 2018005

Group type: EXPERIMENTAL
Intervention: 5-hydroxypropafenone (300 mg, single oral dose)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 7036279

Group type: EXPERIMENTAL
Intervention: Adriamycin-cyclophosphamide (AC) chemotherapy
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: AC chemotherapy plus comprehensive regional radiotherapy
Number of subjects: 138

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 138
Study: 31742488

Group type: EXPERIMENTAL
Intervention: Self-mobilization with movement (S-MWM)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Calf muscle stretching (CMS)
Number of subjects: 38
Study: 31095313

Group type: EXPERIMENTAL
Intervention: Whey Protein Hydrolysate (WPH) 0.08 g/kg BW
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intact Whey Protein (WHEY)
Number of subjects: 10
Study: 28969952

Group type: EXPERIMENTAL
Intervention: Hamstring tendon autograft with preserved insertions (technique 1)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Free hamstring tendon autograft (technique 2)
Number of subjects: 110
Study: 26075373

Group type: EXPERIMENTAL
Intervention: NPWT (negative pressure wound therapy)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Alginate dressings
Number of subjects: 16
Study: 23463811

Group type: EXPERIMENTAL
Intervention: HBPM
Number of subjects: 348

Group type: COMPARATOR
Intervention: UC
Number of subjects: 348
Study: 20883991

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone analogue (GnRH-a; gosareline acetate; Zoladex)
Number of subjects: 40
Study: 19125264

Group type: EXPERIMENTAL
Intervention: EE/DRSP
Number of subjects: 160

Group type: COMPARATOR
Intervention: EE/GSD
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study: 17510720

Group type: EXPERIMENTAL
Intervention: Gingival retraction cord systems (including untreated, medium-braided, and epinephrine-impregnated cords)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gingival retraction cord medicaments
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cord thicknesses
Number of subjects: 16
Study: 15715101

Group type: EXPERIMENTAL
Intervention: Thyroxine 2‐5.2 mg/body mass unit for 1‐10 years (average 4 years)
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Thyroxine therapy
Number of subjects: 1033
Study: 11472741

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg per day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9602957

Group type: EXPERIMENTAL
Intervention: Eprosartan 50 mg, 100 mg, 350 mg once daily or 150 mg every 12 hours
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Eprosartan 600 mg, 800 mg, 1,200 mg once daily
Number of subjects: 57

Group type: COMPARATOR
Intervention: Eprosartan (various doses)
Number of subjects: 57
Study: 8296941

Group type: EXPERIMENTAL
Intervention: On-site medical care at the methadone treatment clinic (n = 25)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Referral to a nearby clinic (n = 26)
Number of subjects: 51
Study: 29232162

Group type: EXPERIMENTAL
Intervention: SAR342434 (SAR-Lis)
Number of subjects: 505

Group type: COMPARATOR
Intervention: Ly‐Lis (Insulin Lispro)
Number of subjects: 505
Study: 27520922

Group type: EXPERIMENTAL
Intervention: Family Schizophrenia Psychoeducation Program (FSPP)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (services as usual, antipsychotic medication)
Number of subjects: 59
Study: 25722080

Group type: EXPERIMENTAL
Intervention: EyeSi(™) simulator
Number of subjects: 42
Study: 23211877

Group type: EXPERIMENTAL
Intervention: 80 mg daily aglycone hypocotyl soy isoflavone supplementation
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: 120 mg daily aglycone hypocotyl soy isoflavone supplementation
Number of subjects: 403

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study: 20067964

Group type: EXPERIMENTAL
Intervention: pioglitazone plus American Diabetes Association (ADA) dietary advice (Pio+ADA)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: pioglitazone plus portion-controlled diet (Pio+PC)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: metformin plus ADA advice (Met+ADA)
Number of subjects: 51
Study: 18483440

Group type: EXPERIMENTAL
Intervention: Elderly participants stepping up
Number of subjects: 25
Study: 16166774

Group type: EXPERIMENTAL
Intervention: Glibenclamide 10.5 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pinacidil 25 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 14578240

Group type: EXPERIMENTAL
Intervention: Multidisciplinary diabetes outreach service (six monthly visits by a traveling team of specialist physicians, nurses, dieticians, and a pharmacist)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Multidisciplinary diabetes outreach service
Number of subjects: 379

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 379
Study: 11113723

Group type: EXPERIMENTAL
Intervention: High-dose lisinopril (daily target dose 32.5-35 mg)
Number of subjects: 3164

Group type: COMPARATOR
Intervention: Low-dose lisinopril (daily target dose 2.5-5.0 mg)
Number of subjects: 3164

Group type: EXPERIMENTAL
Intervention: High-dose lisinopril
Number of subjects: 3164

Group type: COMPARATOR
Intervention: Low-dose lisinopril
Number of subjects: 3164
Study: 9096443

Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rHuEPO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (untreated for the first year)
Number of subjects: 40
Study: 8210967

Group type: EXPERIMENTAL
Intervention: 20 mg of lovastatin combined with 5 g of colestipol
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 20 mg of lovastatin combined with 10 g of colestipol
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 2946972

Group type: EXPERIMENTAL
Intervention: Morphine 5 mg with 5 ml of 1% xylocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine with normal saline 5 ml followed by xylocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline injected epidurally
Number of subjects: 60
Study: 30935555

Group type: EXPERIMENTAL
Intervention: Individualized homeopathy (IH)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control/placebo
Number of subjects: 60
Study: 30458826

Group type: EXPERIMENTAL
Intervention: PD-scale with cutoff score >=4 points
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: PD-scale
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Nurse-researcher PD-scale assessments
Number of subjects: 485
Study: 26808145

Group type: EXPERIMENTAL
Intervention: iPeer2Peer program (peer mentorship program with 10 Skype video calls over 8 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (waitlist control)
Number of subjects: 28
Study: 25213578

Group type: EXPERIMENTAL
Intervention: High-fidelity simulator group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Traditional teaching methods group
Number of subjects: 90
Study: 22618435

Group type: EXPERIMENTAL
Intervention: Wide-volume (non-spiral) mode
Number of subjects: 64

Group type: COMPARATOR
Intervention: Helical mode
Number of subjects: 64
Study: 20399477

Group type: EXPERIMENTAL
Intervention: Five-word test (5WT)
Number of subjects: 504
Study: 18204390

Group type: EXPERIMENTAL
Intervention: Chiropractic visits
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Primary care physician (PCP) visits
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Practitioner visits for headache and neck complaints
Number of subjects: 818
Study: 15737773

Group type: EXPERIMENTAL
Intervention: Concomitant vaccination with Recombivax HB, Td, and MMR vaccines
Number of subjects: 197

Group type: COMPARATOR
Intervention: Nonconcomitant vaccination (HB given at a separate time from Td and MMR)
Number of subjects: 197
Study: 11828239

Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Knee extension strength
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Knee extension strength (normalized per leg lean tissue mass)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Knee flexion strength
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Knee extension strength as predictor
Number of subjects: 75
Study: 9951494

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 238
Study: 8532984

Group type: EXPERIMENTAL
Intervention: Multiple imputation of missing responses using the approximate Bayesian bootstrap
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard endpoint method
Number of subjects: 0
Study: 2268796

Group type: EXPERIMENTAL
Intervention: Intracoronary nifedipine (100 micrograms)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Alcohol-based control solvent
Number of subjects: 15
Study: 215386

Group type: EXPERIMENTAL
Intervention: Dextranomer
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Collagenase
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sugar and egg white
Number of subjects: 17
Study: 30831287

Group type: EXPERIMENTAL
Intervention: Fisher discriminant analysis model for group 1 (meningothelial vs fibrous)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Fisher discriminant analysis model for group 2 (fibrous vs transitional)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Fisher discriminant analysis model for group 3 (meningothelial vs transitional)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Fisher discriminant analysis model for group 4 (meningothelial vs fibrous vs transitional)
Number of subjects: 241
Study: 28936951

Group type: EXPERIMENTAL
Intervention: HFNC
Number of subjects: 49

Group type: COMPARATOR
Intervention: NPPV
Number of subjects: 49
Study: 26328533

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Adjustable gastric banding (AGB)
Number of subjects: 18
Study: 25141084

Group type: EXPERIMENTAL
Intervention: Mental Practice (MP)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Physical Practice (PP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No Practice (NP)
Number of subjects: 36
Study: 22040002

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (uninfected, healthy)
Number of subjects: 44
Study: 19293008

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (400 mg/kg/d for 5 days)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (0 mg/kg/d for 5 days)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (200 mg/kg/d for 5 days)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Safety end point across all treatment groups
Number of subjects: 61
Study: 17440206

Group type: EXPERIMENTAL
Intervention: Instructions prompting a nontrait inference (truth or lie?) for self-informants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Instructions prompting a nontrait inference (truth or lie?) for third-party informants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive load as an explanation for effects
Number of subjects: 0
Study: 16351368

Group type: EXPERIMENTAL
Intervention: Experimental induction of threat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acceptance condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: State Orientation x Stress interaction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: State Orientation x Stress effect
Number of subjects: 0
Study: 12126682

Group type: COMPARATOR
Intervention: Knee splint
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: No splint
Number of subjects: 81
Study: 9477057

Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intralipos infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol in vitro
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol effect on intracellular calcium
Number of subjects: 20
Study: 8550251

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg per os)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (without propranolol)
Number of subjects: 11
Study: 2213104

Group type: EXPERIMENTAL
Intervention: Combined chemo-endocrine therapy (initial treatment)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Endocrine therapy alone (control)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Endocrine therapy alone (control) after crossover to chemotherapy
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Combined treatment (both arms)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Orchiectomy (initial endocrine therapy)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol (DES) (initial endocrine therapy)
Number of subjects: 143
Study: 6780707

Group type: EXPERIMENTAL
Intervention: Casein hydrolysate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactalbumin hydrolysate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fish protein hydrolysate
Number of subjects: 0

Group type: COMPARATOR
Intervention: AA mixtures
Number of subjects: 0
Study: 29911352

Group type: EXPERIMENTAL
Intervention: Topical brimonidine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Air-cooling alone
Number of subjects: 19
Study: 28459239

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided acupotomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Electro-acupuncture (EA)
Number of subjects: 60
Study: 24569698

Group type: EXPERIMENTAL
Intervention: Diabetes self-care coaching intervention delivered by medical assistants
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 270
Study: 22422824

Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: G‐CSF with escalated-dose cytarabine
Number of subjects: 917
Study: 19675321

Group type: EXPERIMENTAL
Intervention: Bayesian hierarchical models (BHMs) for cost-effectiveness analysis
Number of subjects: 1732

Group type: COMPARATOR
Intervention: Standard bivariate regression models
Number of subjects: 1732
Study: 18503773

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a 180 mug/wk plus ribavirin 1000/1200 mg/day for 24 weeks
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a plus ribavirin for 24 weeks
Number of subjects: 516
Study: 15924511

Group type: EXPERIMENTAL
Intervention: Graded exercise therapy (n = 87)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Usual care (n = 89)
Number of subjects: 176
Study: 12908904

Group type: EXPERIMENTAL
Intervention: Oral sip-feed supplement prescribed (120 ml, 22.5 g protein, 2260 kJ (540 kcal) energy/d) three times per day during hospital stay
Number of subjects: 381

Group type: COMPARATOR
Intervention: Routine hospital care
Number of subjects: 381
Study: 10947756

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 7.5 mg combined with preservative‐free ketamine 25 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intrathecal bupivacaine 10 mg alone
Number of subjects: 30
Study: 8818207

Group type: COMPARATOR
Intervention: 15% O2 gas mixture during 100 W and 150 W hindlimb exercises (protocol 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 15% and 10% O2 mixtures during unloaded (0 W) cycling (protocol 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Room air breathing (normoxia)
Number of subjects: 0
Study: 1502426

Group type: EXPERIMENTAL
Intervention: Nimodipine therapy in addition to standard therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard therapy (Control)
Number of subjects: 30
Study: 6488686

Group type: EXPERIMENTAL
Intervention: Diazepam (0.3 mg/kg) before ketamine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl) before ketamine
Number of subjects: 8
Study: 30807424

Group type: EXPERIMENTAL
Intervention: Lidocaine gel (2% transurethral)
Number of subjects: 116
Study: 30261294

Group type: EXPERIMENTAL
Intervention: Community-based multicomponent physical activity program (strength, balance, aerobic) led by trained volunteers or delivered via DVD with coaching and oversight by a fitness professional
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Community-based multicomponent physical activity program
Number of subjects: 1130
Study: 26509827

Group type: EXPERIMENTAL
Intervention: Autologous PRP
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (simulation of PRP administration)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: PRP group
Number of subjects: 71
Study: 26605507

Group type: EXPERIMENTAL
Intervention: Live varicella zoster vaccine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 22732720

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) at P6
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard antiemetic drug therapy (control group)
Number of subjects: 130
Study: 20043005

Group type: EXPERIMENTAL
Intervention: CDP-choline
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 18777490

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 2838

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2838
Study: 15854783

Group type: EXPERIMENTAL
Intervention: High cortisol responses
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low trait avoidance
Number of subjects: 20
Study: 12441832

Group type: EXPERIMENTAL
Intervention: Exercise and toileting intervention (4 times a day, 5 days a week, for 32 weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 51
Study: 10518670

Group type: EXPERIMENTAL
Intervention: SA (5%)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: SAC (10%)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Duofilm (16.7%)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: TSSS (2%)
Number of subjects: 4

Group type: COMPARATOR
Intervention: SAO (10%)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Salic (2.5%)
Number of subjects: 4
Study: 7577874

Group type: EXPERIMENTAL
Intervention: Non-pumiced test groups (no pumice prophylaxis)
Number of subjects: 726

Group type: COMPARATOR
Intervention: Pumiced control groups (with pumice prophylaxis)
Number of subjects: 726
Study: 2031502

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin, and prednisone (CAP)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Cyclophosphamide, 5-fluorouracil, and prednisone (CFP)
Number of subjects: 94
Study: 6222183

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30819689

Group type: EXPERIMENTAL
Intervention: Darkroom prone provocative testing (DRPPT)
Number of subjects: 889

Group type: COMPARATOR
Intervention: Control group (open angles)
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Darkroom prone provocative testing (DRPPT) among PACS with all four quadrants closed
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Darkroom prone provocative testing (DRPPT) among PACS with two or three quadrants closed
Number of subjects: 889
Study: 30059794

Group type: EXPERIMENTAL
Intervention: d-cycloserine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: alprazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: medications (d-cycloserine, alprazolam)
Number of subjects: 0
Study: 27716159

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (20 mg Depo-Medrone)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Night splint
Number of subjects: 240
Study: 24844787

Group type: EXPERIMENTAL
Intervention: PC-SOD (80 mg, intravenous)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (intravenous)
Number of subjects: 80
Study: 22957904

Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 19497461

Group type: EXPERIMENTAL
Intervention: Triage Stroke Panel (D‐dimer, B‐natriuretic peptide, matrix metalloproteinase 9, and S‐100beta)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Combination of nurse assessment and MMX result
Number of subjects: 204

Group type: COMPARATOR
Intervention: Nurse assessment only
Number of subjects: 204
Study: 21415613

Group type: EXPERIMENTAL
Intervention: TEAMcare intervention
Number of subjects: 214

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 214
Study: 15763450

Group type: EXPERIMENTAL
Intervention: montelukast group (n:58)
Number of subjects: 117

Group type: COMPARATOR
Intervention: control group (n:59)
Number of subjects: 117
Study: 12635467

Group type: EXPERIMENTAL
Intervention: Step aerobic training (StA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cycle ergometer training (CET)
Number of subjects: 40
Study: 10624646

Group type: COMPARATOR
Intervention: Promethazine 25 mg (Group 2)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Ondansetron 2 mg plus promethazine 12.5 mg (Group 3, combination)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Combination (ondansetron 4 mg and promethazine 25 mg)
Number of subjects: 87
Study: 7555933

Group type: EXPERIMENTAL
Intervention: Injection sclerotherapy (1% polidocanol)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Laser photocoagulation (Nd:YAG laser)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Laser photocoagulation
Number of subjects: 315

Group type: COMPARATOR
Intervention: Injection sclerotherapy and laser photocoagulation
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Injection sclerotherapy
Number of subjects: 315